David Ha, PharmD, offers insights on how to build out a successful practice-based research project, including developing a strong research question, understanding IRB requirements early, and leveraging reliable institutional data sources and collaborations.
In the second installment of our interview with Andrew Handel, MD, he provides insights on Lyme Disease treatment in the pediatric population.
Stephanie Spivack, MD, discusses an upcoming healthcare provider symposium that will provide education around treating novel infections for patients with substance use disorder (SUD).
The University of Nebraska's Mark Rupp, MD, weighs in on his institution's facilities where passengers are being housed during the quarantine protocol, insights on how they are monitored, and their current medical conditions.
With spring here and tick bites on the rise, Andrew Handel, MD, provides tips on prevention as well as when to consider medical care for a bite.
Federal agencies have airlifted 17 American citizens from the MV Hondius to Nebraska for evaluation and care following exposure to the Andes variant of hantavirus. One passenger currently has mild symptoms and another passenger tested mildly PCR positive for the Andes virus.
Universal childhood immunizations should continue to include hepatitis A to avoid reversing 3 decades of progress toward eliminating the infection, say contributors to the previous, long-standing CDC guidance.
This week, listen to a clinician who has treated hantavirus, SIDP's latest column on the effects of antimicrobials on the microbiome, our podcast looking at how AI can help with stewardship, and more.
Luis A. Marcos, MD, who has treated a patient with hantavirus, provides insights around the Andes virus, which is the species involved in the ongoing outbreak cluster on the cruise ship, as well as its transmissibility and treatment.
Systemic antibiotic therapy often leads to significant long-term disruptions to the gut microbiome. In addition to antibiotic stewardship, use of prebiotic fiber, fermented foods, and probiotics is a recommended strategy to minimize microbiome disruption and reestablish a healthy, diverse gut microbial population.
The growing incidence of resistant Gram-negative infections in hospitals is being fueled by evolving resistance mechanisms, antibiotic overuse, and the rapid global spread of mobile genetic elements. Mariana Castanheira, PhD, FIDSA, FAAM, chief scientific officer at JMI Laboratories, discusses this topic and an agent with utility against pathogens carrying Metallo-beta-lactamases (MBLs).
Eolas Medical has an AI-powered clinical platform looking to aid health care professionals in accessing localized antimicrobial guidelines instantly, improving prescribing accuracy, reducing errors, and strengthening patient safety. CEO Declan Kelly, MBBS, provides insights on the platform and how his company is trying to address gaps in antimicrobial stewardship.
In this month's column, we talk to leaders from professional medical organizations about the revised Advisory Committee on Immunization Practices charter as well as commentary about the Centers for Disease Control and Prevention’s suppression of COVID-19 vaccine data.
Mortality rates from treatment-resistant gram-negative infections remain high despite increased use of newer antibiotics and corresponding susceptibility testing.
This week, read about shorter treatment duration for community-acquired pneumonia, how integrating hepatitis C EMR prompts and innovative community outreach are increasing patients getting tested and treated, and how professional medical organizations are leading the fight for vaccines.
Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses the need to be transparent and publish the latest vaccine data, and offers clinical insights around their safety and efficacy.
Pruthvi Patel, MD, MPH, discusses how she is integrating hepatitis C EMR prompts at her institution as well as their innovative community outreach with educators to get more people into the care continuum.
New real-world data from the CIRCE study underscore cefiderocol’s potential in treating metallo-beta-lactamase–producing Enterobacterales infections, particularly among critically ill and immunocompromised patients with limited therapeutic options. Christine Slover, PharmD, offers some insights around the study and these infections.
In the second episode with Jason M. Goldman, MD, MACP, immediate past president of the American College of Physicians, he discusses the federal government's attempts to suppress studies on vaccine data and how it continues the ongoing antivaccine ideology with further mis- and disinformation.
Gilead Sciences will receive FDA review for its investigational bictegravir/lenacapavir (BIC/LEN) single-tablet HIV regimen, with a decision expected by late summer.
Robert H. Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases, offers commentary about what changing the vaccine committee’s charter means from a functional standpoint and how it affects public health by moving away from vaccines as a prevention strategy.
Jason M. Goldman, MD, MACP, immediate past president of the American College of Physicians, offers insights on what the changing Advisory Committee on Immunization Practices charter means and legal steps the college is taking to prevent the federal government’s attempt to reshape the group and vaccine policy in the US.
Real-world data suggest that 3 to 4 days of antibiotics can be as effective as 5 or more days in treating community-acquired pneumonia in hospitalized patients.
A study assessing the local transmission found it caused 14 confirmed cases in 2024 and exposed diagnostic delays in patients without travel history.
This week, read a clinician's insights on a new FDA-approved HIV therapy, the CDC cancels publication of a COVID-19 vaccine study, moving up hepatitis C cure timelines, and more.
Doravirine/islatravir (Idvynso), is a non-INSTI, tenofovir-free alternative for virologically suppressed adults, with efficacy, safety, and potential benefits for aging populations managing complex treatment needs. Amy Colson, MD, MPH, offers some insights about the phase 3 trial and how clinicians may want to consider its use for patients.
Jonathan Batchelder, PhD, provides insights around his research that showed that Staphylococcus aureus can survive fluoroquinolone treatment under nutrient-limited conditions even without key DNA repair proteins, pointing to alternative survival pathways and implications for future therapies.
Emerging evidence suggests that confirming hepatitis C cure at 4 weeks post-treatment could improve patient engagement and reduce barriers to care without compromising accuracy. Meghan D. Morris, PhD, MPH, offers insights around her study on this subject.
The agency’s acting director took the unusual step of withholding the publication of the study findings in the Morbidity and Mortality Weekly Report, which showed the vaccine was protective against hospitalization and emergency department visits.
Results from a large population-based study found that receiving influenza and pertussis vaccines on the same day during pregnancy does not increase the risk of adverse maternal, birth, or neonatal outcomes compared with pertussis vaccination alone.
